02/03/2026
๐
๐๐ ๐๐๐๐๐๐ ๐๐ ๐๐๐ ๐๐๐๐๐๐๐๐๐ ๐๐๐๐๐๐ ๐๐
๐๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐ ๐๐๐๐๐๐ ๐๐๐๐๐๐๐ ๐๐๐๐๐๐๐๐
The Food and Drug Administration provides the public with an update on the voluntary recall of selected batches of NAN OPTIPRO and NANKID OPTIPRO products initiated by Nestlรฉ Philippines, Inc.
A total of 39 batches, equivalent to 330,004 units manufactured at the Cabuyao plant, were included in the precautionary recall. Production of the affected products was halted on 25 December 2025.
For the latest status on the matter:
1. One hundred percent of all segregated recalled products are now under the control of Nestlรฉ Philippines.
2. Approximately sixty percent of the affected products, totaling 199,414 units, are scheduled for destruction.
3. The FDA, through its regulatory and enforcement unit, will take part in the scheduled destruction of the recalled products to ensure proper compliance with recall procedures.
With respect to consumer concerns, as of date, all complaints received directly by the FDA have already been referred to and handled by the company. Nestlรฉ has likewise reported that a majority of complaints received directly by it have been addressed, with continuous monitoring and follow-up.
The FDA recognizes and understands the concern of parents and caregivers when it comes to infant nutrition products. The Agency continues to exercise strict regulatory oversight over the recall process, including verification of documentation, inspection activities, and supervision of product destruction to ensure full compliance with existing regulations.
Parents and caregivers are encouraged to remain attentive to official FDA advisories and report any concerns through the FDAโs eSumbong platform available on the official FDA website, or via email at ๐๐ง๐๐ฅ๐ค๐ง๐ฉ@๐๐๐.๐๐ค๐ซ.๐ฅ๐.
The FDA remains committed in safeguarding public health, particularly the safety and well-being of infants and young children. Further updates will be issued as warranted, consistent with verified findings and established regulatory processes.
